PAIOF (Paion AG) Forward Dividend Yield %: 0.00% (As of Jun. 25, 2026)


PAIOF Paion AG PAIOF
10 GF Score
Price $0.01
View Full Analysis

What is Paion AG Forward Dividend Yield %?

Paion AG PAIOF +9,900.00% 10 Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus rates PAIOF with a GF Score™ of 10/100.

As of today (2026-06-25), the Forward Annual Dividend Yield of Paion AG is 0.00%.

As of today (2026-06-25), the Trailing Annual Dividend Yield of Paion AG is 0.00%.

PAIOF's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.095
* Ranked among companies with meaningful Forward Dividend Yield % only.

Paion AG's Dividends per Share for the six months ended in Jun. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Paion AG  (OTCPK:PAIOF) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Paion AG Forward Dividend Yield % Related Terms

PAIOF vs ZTS, NBIX, VTRS: Forward Dividend Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Paion AG's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paion AG Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion AG's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Paion AG's Forward Dividend Yield % falls into.


PAIOF
10GF Score
Paion AG PAIOF
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paion AG Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Paion AG (PAIOF) has a Forward Dividend Yield % of 0.00% as of Jun. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Paion AG and its competitors.
Is Paion AG's Forward Dividend Yield % too high?
Paion AG's current Forward Dividend Yield % is 0.00%. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's Forward Dividend Yield % compare to ZTS and NBIX?
Paion AG's Forward Dividend Yield % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median Forward Dividend Yield % is 2.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.10, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Paion AG and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paion AG's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Paion AG (PAIOF), the current Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paion AG Business Description

Address Heussstrasse 25, Aachen, DEU, 52078
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score

Get the complete analysis for PAIOF

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price